TRX518

BIOLOGICAL2 trials

Sponsors

Leap Therapeutics, Inc.

Conditions

Advanced Hormone Receptor Positive/Endocrine Refractory Breast CancerAdvanced Metastatic Castration-Resistant Prostate CancerAdvanced Platinum-Resistant Ovarian CancerAdvanced Triple Negative Breast CancerSolid TumorsUnresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Phase 1

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

CompletedNCT01239134

Leap Therapeutics, Inc.Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Start: 2010-10-31End: 2018-09-30Updated: 2025-08-03

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

TerminatedNCT03861403

Leap Therapeutics, Inc.Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer +2

Start: 2019-05-20End: 2020-07-14Updated: 2023-11-30

Related Papers

Abstract IA04: Overcoming immune resistance with rationally designed combination immunotherapy

Cancer Research2020-10-01

Abstract 2711: Rational combination of GITR agonism with PD-1 blockade

Cancer Research2019-07-011 citations

Abstract 2711: Rational combination of GITR agonism with PD-1 blockade

Immunology2019-07-011 citations

Rational design of anti-GITR-based combination immunotherapy.

2019-04-29174 citations

Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients

Cancer Immunology Research2019-02-011 citations

Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial

Cancer Research2017-07-017 citations

First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.

Journal of Clinical Oncology2016-05-2035 citations